PubMed=26715207; DOI=10.1002/cbin.10574
Herzog N., Hansen M., Miethbauer S., Schmidtke K.-U., Anderer U., Lupp A., Sperling S., Seehofer D., Damm G., Scheibner K., Kupper J.-H.
Primary-like human hepatocytes genetically engineered to obtain proliferation competence display hepatic differentiation characteristics in monolayer and organotypical spheroid cultures.
Cell Biol. Int. 40:341-353(2016)

DOI=10.17169/refubium-1249
Sperling S.
Genetically modified Upcyte(R) hepatocytes as a powerful alternative to primarily human hepatocytes and the hepatocellular carcinoma cell line HepG2 in the in vitro steatosis model.
Thesis MD (2018); Charite - Universitatsmedizin Berlin; Berlin; Germany

PubMed=30347615; DOI=10.3233/CH-189321
Kammerer S., Kupper J.-H.
Optimized protocol for induction of cytochrome P450 enzymes 1A2 and 3A4 in human primary-like hepatocyte cell strain HepaFH3 to study in vitro toxicology.
Clin. Hemorheol. Microcirc. 70:563-571(2018)

PubMed=31561354; DOI=10.3233/CH-199226; PMCID=PMC6918903
Schulz C., Kammerer S., Kupper J.-H.
NADPH-cytochrome P450 reductase expression and enzymatic activity in primary-like human hepatocytes and HepG2 cells for in vitro biotransformation studies.
Clin. Hemorheol. Microcirc. 73:249-260(2019)